Derek M. Meisner
Known title: Chief Legal OfficerCIK: 0001752461
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
Transaction History
| ABOS | ▲ Buy | Option Exercise | 2,090 | $4K | 3/6/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 2,090 | $7K | 3/6/2026 | View on chart |
| ABOS | ▲ Buy | Option Exercise | 9,406 | $17K | 2/27/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 9,406 | $28K | 2/27/2026 | View on chart |
| ABOS | ▲ Buy | Option Exercise | 2,671 | $5K | 1/28/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 2,671 | $8K | 1/28/2026 | View on chart |
| ABOS | ▲ Buy | Option Exercise | 15,085 | $28K | 1/26/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 15,085 | $45K | 1/26/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 5,633 | $11K | 1/23/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 1,054 | $2K | 1/22/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 2,247 | $4K | 1/21/2026 | View on chart |
| ABOS | ▲ Buy | Grant | 99,133 | $0 | 1/16/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 8,548 | $15K | 1/12/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 5,200 | $9K | 1/9/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 30,092 | $55K | 1/8/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 6,819 | $12K | 1/8/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 1,700 | $3K | 1/7/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 10,070 | $20K | 1/7/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 7,097 | $14K | 1/6/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 3,801 | $7K | 1/6/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 4,000 | $8K | 1/5/2026 | View on chart |
| ABOS | ▼ Sell | Open Market | 3,418 | $5K | 1/21/2025 | View on chart |
| ABOS | ▲ Buy | Grant | 66,800 | $0 | 1/6/2025 | View on chart |
| ABOS | ▼ Sell | Open Market | 11,122 | $21K | 1/3/2025 | View on chart |
| ABOS | ▼ Sell | Open Market | 8,933 | $31K | 1/19/2024 | View on chart |
| ABOS | ▲ Buy | Grant | 91,000 | $0 | 1/2/2024 | View on chart |
| ABOS | ▲ Buy | Grant | 26,800 | $0 | 1/17/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 8,334 | — | 8/17/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 4,166 | — | 6/24/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 4,166 | — | 6/16/2022 | View on chart |
| XFOR | ▲ Buy | Grant | 105,000 | $0 | 3/1/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 15,909 | — | 2/11/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 8,332 | $42K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List
Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.
Acumen Pharmaceuticals Featured in Alzheimer's Day Stock List. Acumen Pharmaceuticals was included in a Yahoo Finance article highlighting four Alzheimer's drug stocks to watch on World Alzheimer's Day. The mention serves as a reminder of the company's focus on neurodegenerative diseases, though the article does not report any new clinical data or corporate announcements. The stock is currently trading near its 52-week low, with an average analyst target of $7.60.